ClinicalTrials.gg
CompletedNCT06066099Updated Jul 14, 2025

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969

A Phase 1 interventional study of AP31969 and Placebo in Healthy Volunteers, sponsored by Acesion Pharma. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Acesion Pharma · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Arrhythmias, Cardiac with a site in Netherlands — 13 open to participants now, 18 under way, none of them phase 3. Arrhythmias, Cardiac · Netherlands.

Enrollment
25th of 33
92 · median 240
Started
2023
with 5 others
Phase 1
Only one
of the 72
Registered
65th of 72
by date

Among the 72 studies in Arrhythmias, Cardiac with a site in Netherlands, this one is the 25th largest by enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2023, is the only one in phase 1, and was the 65th registered.

Arrhythmias, Cardiac

1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

13 of the 72 studies in Arrhythmias, Cardiac with a site in Netherlands are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 167 Arrhythmias, Cardiac studies recruiting now, 118 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Arrhythmias, Cardiac with a site in Netherlands, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the safety and tolerability of single doses (Part A) and multiple doses (Part B) of AP31969 in healthy participants.

03

Conditions studied

  • Healthy Volunteers

Keywords

  • Antiarrhythmic agent
  • Cardiac arrhythmia
  • Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age : 18 years to 55 years, inclusive, at screening.
  2. Weight: ≥50 kg, at screening.
  3. : 18.0 kg/m\^2 to 30.0 kg/m\^2, inclusive, at screening.
  4. Sex : male or female; female participants may be of or of nonchildbearing potential (either surgically sterilized, physiologically incapable of becoming pregnant, or at least 1 year [amenorrhea duration of 12 consecutive months] and confirmed by a follicle-stimulating hormone test at screening).
  5. In good physical and mental health on the basis of medical history, physical examination, clinical laboratory, 12-lead (ECG), and vital signs, as judged by the Investigator.
  6. Resting supine systolic blood pressure (BP) (average of 3 readings) between 140 and 90 mmHg (inclusive, at screening and [each] admission), and diastolic BP (average of 3 readings) between 90 and 50 mmHg (inclusive, at screening and [each] admission). If initial results do not meet these criteria, BP may be repeated if in the judgment of the Investigator there is a reason to believe the initial result is inaccurate (eg, white coat hypertension).
  7. Computerized (12-lead) ECG recording without signs of pathology and with a -interval with Fridericia's correction (QTcF-interval) interval between 300 and 450 ms, inclusive, at screening and (each) admission.
  8. Female participants must not be pregnant or lactating. Nonpregnancy will be confirmed for all female participants by a negative serum pregnancy test at screening and (each) admission.
  9. Female participants of childbearing potential who have a fertile male sexual partner must agree to use highly effective and not donate ova from 4 weeks prior to (the first) study drug administration until 90 days after the follow-up visit.
  10. Male participants, if not surgically sterilized, who have a female sexual partner of childbearing potential must agree to use highly effective contraception and not donate sperm from (first) admission until 90 days after the follow-up visit.
  11. Able to swallow up to 9 tablets of study drug (based on participant's own judgment after being informed about the possible number of tablets and the size of the tablets).
  12. Willing and able to understand and comply with the protocol requirements, restrictions, and instructions listed in the form (ICF) and in the protocol and likely to complete the study as planned.
  13. Willing and able to sign the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in the current study.
  2. Employee of ICON or the Sponsor.
  3. History of relevant drug and/or food allergies.
  4. History of any illness or condition that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk when administering the study drug to the subject (with particular focus on cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, cerebrovascular, and neurological diseases including history of syncope and/or convulsions).
  5. History of any major disorder capable of significantly altering the absorption, metabolism, or elimination of the study drug, constituting a risk when taking the study drug, or interfering with the interpretation of data in the opinion of the Investigator.
  6. Personal or first-degree relative family history of congenital long syndrome or sudden death.
  7. Presence of any signs of tremor in rest at screening or (at one of the) admission(s) to the clinical research center.
  8. Use of any prescribed medication within 30 days prior to (first) admission, based on Investigator's judgment. An exception is made for hormonal , which may be used throughout the study.
  9. Use of any over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John's wort) within 14 days prior to (first) admission, based on Investigator's judgment. An exception is made for acetaminophen/paracetamol, which is allowed up to 2 g/day.
  10. Positive screen for surface antigen, virus antibodies, or 1 and 2 antibodies, at screening. In case of vaccination against these diseases, inclusion is allowed.
  11. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening or (at one of the) admission(s) to the clinical research center.
  12. Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits).
  13. History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within 2 years prior to screening.
  14. Smoking on average more than 5 cigarettes, 1 cigar, or 1 pipe daily.
  15. Participation in another drug study within 30 days prior to (the first) study drug administration in the current study, or in 4 or more drug studies within 12 months prior to (the first) study drug administration in the current study.
  16. Donation or loss of more than 450 mL of blood within 60 days prior to (the first) study drug administration.
  17. Significant and/or acute illness within 5 days prior to (the first) study drug administration that may impact safety assessments, in the opinion of the Investigator.
  18. Unsuitable veins for blood sampling.
  19. For the food effect group only: unwilling to consume high-fat, high-calorie meal.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Part A: Single Ascending Doses

    Participants will be randomized to receive a single oral dose of AP31969 or matching placebo in 1 of 5 groups. Participants in an additional food effect assessment group will be randomized to receive 2 single oral doses of AP31969 or matching placebo; 1 dose in fasted and 1 dose in fed state in a 2-period, fixed-sequence design (first fasted, then fed with at least 1 week washout between periods).

    Drug: AP31969 · Drug: Placebo

  • Experimental
    Part B: Multiple Ascending Doses

    Participants will be randomized to receive multiple oral doses of AP31969 or matching placebo for 10 days in 1 of 4 groups.

    Drug: AP31969 · Drug: Placebo

Interventions

  • Oral tablets

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Number of Participants who Experienced an Adverse Event

    Time frame: Up to a maximum of 48 days

Secondary outcomes

  1. Parts A and B: Maximum Observed Plasma Concentration (Cmax) of AP31969

    Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 12

  2. Parts A and B: Time to Cmax (tmax) of AP31969

    Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 12

  3. Parts A and B: Terminal Elimination Half-life of AP31969

    Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 12

  4. Part A: Area Under the Plasma Concentration Time Curve (AUC) from Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of AP31969

    Time frame: Part A: Day 1 to Day 4

  5. Part A: AUC from Time 0 Extrapolated to Infinity (AUC0-inf) of AP31969

    Time frame: Part A: Day 1 to Day 4

  6. Part B: AUC Over a Dosing Interval Tau (AUCtau) of AP31969

    Time frame: Part B: Day 1 to Day 10

  7. Part A: Apparent Clearance of AP31969

    Time frame: Part A: Day 1 to Day 4

  8. Part B: Apparent Clearance at Steady State of AP31969

    Time frame: Part B: Day 1 to Day 10

  9. Parts A and B: Apparent Volume of Distribution at Terminal Phase of AP31969

    Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 10

  10. Part B: Accumulation Ratio of AP31969

    Time frame: Part B: Day 1 to Day 10

  11. Parts A and B: Dose Normalized Cmax of AP31969

    Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 10

  12. Part A: Dose Normalized AUC0-last of AP31969

    Time frame: Part A: Day 1 to Day 4

  13. Part A: Dose Normalized AUC0-inf of AP31969

    Time frame: Part A: Day 1 to Day 4

  14. Part B: Dose Normalized AUCtau of AP31969

    Time frame: Part B: Day 1 to Day 10

  15. Part A: Food Effect on Cmax of AP31969

    Time frame: Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group

  16. Part A: Food Effect on AUC0-last of AP31969

    Time frame: Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group

  17. Part A: Food Effect on AUC0-inf of AP31969

    Time frame: Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group

07

Study locations

1 site
  • Acesion Pharma Investigational Site 10
    Groningen, 9728, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Mar 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartActual
Oct 4, 2023
Primary completionActual
Mar 14, 2025
CompletionActual
Mar 14, 2025
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06066099
Lead sponsor
Acesion Pharma
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Oct 4, 2023
Primary completion
Mar 14, 2025
Completion
Mar 14, 2025
Last update
Jul 14, 2025

Study contacts

Director Clinical Operations
study director · Acesion Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP31969

Start the discussion